Wedbush Reiterates Buy Rating on TCRX
Wedbush reaffirms TCRX with a $5 price target as shares trade around $0.86, a 467.54% upside from the current price.
Key Points
- On June 23, 2026, Wedbush reiterated its buy rating on TCRX, setting a price target of $5.
- Wedbush's $5 price target implies 467.54% upside from TScan Therapeutics, Inc.'s ($TCRX) current $0.88 share price.
- Shares of TCRX traded near $0.86 on Tuesday, reflecting ongoing interest from analysts and investors.
- Recent insider buying activity and institutional moves highlight continued interest in TCRX.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, Wedbush reiterated its buy rating on TCRX, maintaining a price target of $5. Analyst David Nierengarten reaffirmed the outlook as shares traded around $0.86 on Tuesday.
Wedbush vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in TCRX
Several institutional investors have recently updated their positions in TCRX. LYNX1 Capital Management LP held steady with 8,019,148 shares valued at about $8.1 million. BVF Inc/IL increased its stake by 338,216 shares, now holding 5,564,290 shares worth approximately $5.6 million, a 6.5% increase. Vanguard Capital Management LLC opened a new position with 2,154,256 shares valued at $2.2 million. Meanwhile, BlackRock, Inc. slightly reduced its holdings by 7,743 shares, now owning 1,840,952 shares valued at $1.9 million, a 0.4% decrease.
TScan Therapeutics, Inc. Stock Up 16.9%
Shares of TCRX traded near $0.86 on Tuesday. The stock's recent movements reflect a continued interest from both investors and analysts, with institutional activities and insider transactions indicating varied strategies around the stock.
$TCRX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at TScan Therapeutics, Inc.
Insider buying activity was notable on May 20, 2026. Several insiders, including Barbara Klencke, Gabriela Gruia, Keith Woods, Katina Dorton, and Garry Nicholson, each purchased 67,000 shares. These transactions were not part of any pre-planned 10b5-1 plans, suggesting a direct vote of confidence in the company's future.
Analysts Set New Price Targets
On June 23, 2026, Wedbush reiterated its buy rating on TCRX with a $5 price target. Needham also reiterated its buy rating, setting a price target of $6 on the same day. The consensus among analysts is a buy rating, with a mean price target reflecting optimism about the stock's potential.
Bottom Line
TCRX has caught the attention of analysts and investors alike, with Wedbush's reaffirmed buy rating and $5 price target underscoring positive sentiment. The stock's price near $0.86 indicates ongoing interest, despite fluctuations. Insider purchases and institutional adjustments suggest strategic positioning as market participants await further developments. Keep in mind, these analyst ratings and institutional filings are backward-looking and reflect past decisions.
Get TScan Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TCRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.